Sign In
Buy NRXP
$4.05
-0.570 (-12.34%)
At Close: Jun 03, 2026
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
07:00am, Monday, 02'nd Mar 2026
WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown,
NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER)
New Strong Sell Stocks for January 27th
05:06am, Tuesday, 27'th Jan 2026
DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
07:03am, Friday, 16'th Jan 2026
WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annua
WILMINGTON, Del., Jan. 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has licensed Real World Evidence (RWE)
Head-To-Head Review: Universe Pharmaceuticals (NASDAQ:UPC) and NRx Pharmaceuticals (NASDAQ:NRXP)
02:16am, Wednesday, 14'th Jan 2026
NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) and Universe Pharmaceuticals (NASDAQ: UPC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare
WILMINGTON, Del. and MUNICH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company and neurocare Group AG today (“The Partners”) an
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Recommendation of “Moderate Buy” from Analysts
01:23am, Friday, 02'nd Jan 2026
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat Ratings reports. O
Comparing NRx Pharmaceuticals (NASDAQ:NRXP) & Salarius Pharmaceuticals (NASDAQ:SLRX)
01:42am, Friday, 19'th Dec 2025
Salarius Pharmaceuticals (NASDAQ: SLRX - Get Free Report) and NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will con
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
07:05am, Thursday, 18'th Dec 2025
WILMINGTON, Del., Dec. 18, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has repaid the remaining $5.4 million
Critical Analysis: USANA Health Sciences (NYSE:USNA) vs. NRx Pharmaceuticals (NASDAQ:NRXP)
01:59am, Sunday, 14'th Dec 2025
USANA Health Sciences (NYSE: USNA - Get Free Report) and NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare th
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of “Moderate Buy” from Analysts
01:10am, Monday, 08'th Dec 2025
Shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat
NRx Pharmaceuticals to discuss new NRX-101 pipeline indication for augmentation of Transcranial Magnetic Stimulation
07:00am, Wednesday, 03'rd Dec 2025
WILMINGTON, Del., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has amended its Investigational New Dr
NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript
NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine
08:30am, Tuesday, 02'nd Dec 2025
WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FD
